Agenus (NASDAQ:AGEN) Upgraded by Wall Street Zen to “Buy” Rating

Agenus (NASDAQ:AGEN) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Monday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Agenus in a research report on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $14.50.

Agenus Stock Performance

Agenus stock opened at $3.33 on Monday. The company has a fifty day simple moving average of $3.20 and a 200-day simple moving average of $3.68. The stock has a market cap of $127.87 million, a P/E ratio of -7.24 and a beta of 1.60. Agenus has a 12-month low of $1.38 and a 12-month high of $7.34.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Monday, March 16th. The biotechnology company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.27) by $1.83. The firm had revenue of $34.20 million during the quarter, compared to the consensus estimate of $28.10 million. Agenus had a negative return on equity of 7.65% and a negative net margin of 2.67%. As a group, sell-side analysts forecast that Agenus will post -12.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Agenus

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of Agenus by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,569,533 shares of the biotechnology company’s stock valued at $9,893,000 after purchasing an additional 36,983 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Agenus by 721.1% during the 4th quarter. Renaissance Technologies LLC now owns 543,546 shares of the biotechnology company’s stock worth $1,707,000 after purchasing an additional 477,346 shares during the period. AQR Capital Management LLC increased its position in Agenus by 3,080.3% during the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock worth $664,000 after purchasing an additional 427,604 shares in the last quarter. Marshall Wace LLP acquired a new stake in Agenus during the 2nd quarter worth approximately $1,976,000. Finally, Bank of America Corp DE raised its holdings in Agenus by 110.0% in the second quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock valued at $1,922,000 after buying an additional 220,327 shares during the period. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus News Summary

Here are the key news stories impacting Agenus this week:

• Positive Sentiment: Zacks upgraded AGEN to a Zacks Rank #1 (Strong Buy), signaling increased analyst optimism that may attract buyer interest and momentum traders. All You Need to Know About Agenus (AGEN) Rating Upgrade to Strong Buy
• Positive Sentiment: Zacks flagged rising earnings estimate revisions as a reason AGEN could move higher — reinforcing the upgrade and suggesting analyst models are shifting toward better near‑term results. Can Agenus (AGEN) Run Higher on Rising Earnings Estimates?
• Positive Sentiment: HC Wainwright materially raised several near‑term EPS forecasts (notably Q1 and full‑year FY2026), lifting quarter and FY2026 estimates — a catalyst that can re‑rate the stock if investors believe earnings will improve meaningfully. (Research note summaries)
• Positive Sentiment: Clinical progress: Agenus announced first patient enrolled in the global Phase III BATTMAN trial (BOT+BAL) for MSS/pMMR metastatic colorectal cancer — Phase III starts and patient accrual milestones are commonly positive near‑term catalysts. Agenus enrols first patient in BATTMAN Phase III trial
• Positive Sentiment: Scientific visibility: Data from a Phase II investigator‑initiated study of BOT+BAL with agenT‑797 will be presented at AACR 2026 — upcoming conference exposure can boost investor confidence ahead of or after poster/oral presentation. Agenus Announces Data from Phase II Study … to be Presented at AACR 2026
• Neutral Sentiment: Zacks published broader pieces framing AGEN as a momentum/value/growth idea and compared sector performance — useful for traders but less likely to move the stock materially on its own. Why Agenus (AGEN) is a Top Momentum Stock for the Long-Term Has Agenus (AGEN) Outpaced Other Medical Stocks This Year?
• Negative Sentiment: HC Wainwright trimmed some longer‑range estimates (FY2029 and FY2030) even as it lifted near‑term numbers — a reminder that longer‑term profitability remains uncertain and could limit sustained multiple expansion if future guidance weakens. (Research note summaries)

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.